A newly published study in Hypertension Research suggests that tirzepatide — the active ingredient in Mounjaro and Zepbound — may do more than control blood sugar and body weight. Researchers investigated its effects on blood pressure, cardiac function, and the sympathetic nervous system, adding to a growing body of evidence that the drug could offer meaningful cardiovascular benefits.
What the Research Found
The study examined tirzepatide in stroke-prone spontaneously hypertensive rats, a well-established animal model used to study high blood pressure and its complications. Tirzepatide is a dual agonist, meaning it activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously — a mechanism that sets it apart from GLP-1-only medications like semaglutide (Ozempic, Wegovy).
The research builds on earlier clinical findings that in obese patients with heart failure with preserved ejection fraction (HFpEF), tirzepatide reduced weight, lowered blood pressure, and improved outcomes — results that have generated significant scientific interest in the drug's cardiovascular potential.
Why This Matters for Patients
Many people taking Mounjaro or Zepbound already have high blood pressure or are at elevated cardiovascular risk, often because obesity and type 2 diabetes are closely linked to heart disease. If tirzepatide independently supports healthier blood pressure and cardiac function — beyond the benefits of weight loss alone — that could make it an especially valuable option for people managing multiple conditions at once.
It is important to note, however, that this study was conducted in rats, not humans. Animal research provides useful early signals but does not automatically translate to the same effects in people. Larger human clinical trials are needed before firm conclusions can be drawn.
Key takeaway: While this animal study suggests tirzepatide may support lower blood pressure and better heart function, it is preliminary research. Talk to your prescriber before making any changes to your medication or treatment plan based on these findings.
The Bigger Picture on GLP-1s and Heart Health
Interest in the cardiovascular effects of GLP-1 receptor agonists has been growing steadily. Tirzepatide's dual GIP and GLP-1 receptor activity is a distinct pharmacological profile, and researchers are actively working to understand whether that dual action provides added heart and blood pressure benefits beyond what single-receptor GLP-1 drugs offer. This new study is part of that ongoing scientific conversation.
What to Watch Next
Researchers will need to follow up with human studies specifically designed to measure tirzepatide's direct effects on blood pressure and cardiac function, separate from weight loss. Patients and clinicians should watch for results from cardiovascular outcome trials and any new regulatory guidance that may emerge as the evidence base grows.
Frequently Asked Questions
As research into tirzepatide's cardiovascular effects continues to evolve, the most important step you can take is to discuss your individual risk factors — including blood pressure and heart health — with your prescriber, who can help tailor your treatment plan to your specific needs.
- Peer-reviewed journal article, 'Effects of tirzepatide, a dual GIP and GLP-1 receptor agonist, on blood pressure, cardiac function, and sympathetic nervous system in stroke-prone spontaneously hypertensive rats,' Hypertens Res, date not specified in source material.